What question did this study set out to answer?

To determine the global prevalence, incidence, progression, and clinical outcomes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

December 28, 2015Hepatology

Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

View Full Paper

Ask AI

Bookmark

To determine the global prevalence, incidence, progression, and clinical outcomes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Searched PubMed/MEDLINE from 1989 to 2015, analyzing 86 eligible studies comprising 8,515,431 individuals across 22 countries after excluding cohorts restricted to morbidly obese, diabetic, or pediatric groups.
Employed random-effects meta-analytic models and subgroup metaregressions stratified by world region, diagnostic modality, biopsy indication, and study population.
Global prevalence of NAFLD was 25.24% (95% CI: 22.10–28.65), with highest rates in the Middle East and South America, frequently co-occurring with hyperlipidemia (69.16%; 95% CI: 49.91–83.46), obesity (51.34%; 95% CI: 41.38–61.20), metabolic syndrome (42.54%; 95% CI: 30.06–56.05), hypertension (39.34%; 95% CI: 33.15–45.88), and type 2 diabetes (22.51%; 95% CI: 17.92–27.89).
Fibrosis progression occurred in 40.76% (95% CI: 34.69–47.13) of NASH cases, with an HCC incidence of 0.44 per 1,000 person-years (range, 0.29–0.66) and an elevated risk for liver-specific mortality among NAFLD patients (IRR 1.94; range, 1.28–2.92).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Meta-analysis reveals a 25.2% prevalence of NAFLD and significant liver mortality across worldwide populations, highlighting an escalating global clinical and economic burden.

Cite This Study

Younossi et al. (2015) studied this question.

synapsesocial.com/papers/69699d38e0e11f4d2ddfd7ff https://doi.org/10.1002/hep.28431

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis reveals a 25.2% prevalence of NAFLD and significant liver mortality across worldwide populations, highlighting an escalating global clinical and economic burden.

Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

Key Points

Discussion

Implication

Cite This Study

Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider